ACCP Urges Passage of Legislation Covering Clinical Pharmacist Consultations

May 12, 2022

-- Key House Chairman Pledges Continued Work to Advance the Measure --

Washington, DC (May 12, 2022) -- ACCP is urging the U.S. House Energy and Commerce Committee to pass H.R. 6000, the “CURES 2.0 Act,”  legislation that would accelerate development and coverage of health cures, treatments, and other medical innovations. The bill also includes a groundbreaking provision to establish a Medicare benefit for pharmacogenetic consultations by qualified clinical pharmacists. 

The bill, introduced by Representatives Diana DeGette (D-Colorado) and Fred Upton (R-Michigan), has been referred to the Energy and Commerce Committee for consideration. The panel’s Health Subcommittee held a legislative “mark-up” session Wednesday on several bills. In a letter to Committee Chairman Frank Pallone (D-New Jersey) and Ranking Republican Member Cathy McMorris-Rodgers (R-Washington) prior to the mark-up, ACCP urged swift passage of CURES 2.0. 

In opening remarks during the session, Chairman Pallone indicated that while CURES 2.0 was not part of the subcommittee’s action that day, he would seek additional input and opportunities to advance the legislation.

“ACCP is pleased that the committee will continue its work on this important bill,” said Michael Maddux, ACCP Executive Director. “The legislation includes recognition of the work of clinical pharmacists in the provision of pharmacogenetic consultations,” he continued.  “This will serve as another key step toward achieving widespread acknowledgement of the value of clinical pharmacy services in team-based, collaborative settings.”